Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B
- PMID: 15561860
- PMCID: PMC529246
- DOI: 10.1128/AAC.48.12.4808-4812.2004
Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B
Abstract
We assessed the activity and safety of liposomal nystatin, a broad-spectrum antifungal agent, for invasive aspergillosis in patients refractory to or intolerant of amphotericin B. Thirty-three patients were enrolled, received at least one dose of the study drug, and were evaluable for safety. Twenty-six patients had confirmed probable or definite aspergillosis and were fully eligible. Most patients had a hematological malignancy (53.8%) or hematopoietic stem cell transplantation (23.0%), were neutropenic (61.5%), and were refractory to previous amphotericin B (92.3%). The median duration of previous amphotericin B treatment was 16.5 days (range, 5 to 64 days). Aspergillosis was definite in 3 cases and probable in 23 cases. Liposomal nystatin was initiated at a dose of 4 mg/kg of body weight/day. Twenty-five patients were evaluable for response: a complete response was achieved for one patient, and a partial response was achieved for six. Thus, the overall response rate is 7 of 25 (28%; 95% confidence interval, 12 to 49%). Seventeen (68.0%) of the 25 evaluable patients died during therapy or within 1 month after the end of therapy. The primary cause of death was invasive aspergillosis for nine patients and underlying malignancy for eight patients. The most frequent side effects included chills, shivering, and fever, leading to discontinuation of therapy for two patients. Grade 1 decline in renal function was seen for 10 (30.3%) patients, and hypokalemia was seen for 13 (39.4%). We conclude that liposomal nystatin can be effective for salvage therapy of invasive aspergillosis. Infusion-related adverse events have been observed frequently.
Similar articles
-
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.N Engl J Med. 2002 Aug 8;347(6):408-15. doi: 10.1056/NEJMoa020191. N Engl J Med. 2002. PMID: 12167683 Clinical Trial.
-
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).Clin Infect Dis. 2007 May 15;44(10):1289-97. doi: 10.1086/514341. Epub 2007 Apr 9. Clin Infect Dis. 2007. PMID: 17443465 Clinical Trial.
-
Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.Cancer. 2008 Mar 15;112(6):1282-7. doi: 10.1002/cncr.23311. Cancer. 2008. PMID: 18224662
-
Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.Haematologica. 1997 May-Jun;82(3):297-304. Haematologica. 1997. PMID: 9234575 Review.
-
Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?J Chemother. 2011 Feb;23(1):5-8. doi: 10.1179/joc.2011.23.1.5. J Chemother. 2011. PMID: 21482486 Review.
Cited by
-
Efficacy of Liposomal Nystatin in a Rabbit Model of Cryptococcal Meningitis.J Fungi (Basel). 2024 Jul 26;10(8):520. doi: 10.3390/jof10080520. J Fungi (Basel). 2024. PMID: 39194846 Free PMC article.
-
Water-Soluble Nystatin and Derivative.ACS Med Chem Lett. 2022 Jan 20;13(2):182-187. doi: 10.1021/acsmedchemlett.1c00538. eCollection 2022 Feb 10. ACS Med Chem Lett. 2022. PMID: 35178173 Free PMC article.
-
Fungal Genomics in Respiratory Medicine: What, How and When?Mycopathologia. 2021 Oct;186(5):589-608. doi: 10.1007/s11046-021-00573-x. Epub 2021 Sep 7. Mycopathologia. 2021. PMID: 34490551 Free PMC article. Review.
-
Modeling Invasive Aspergillosis: How Close Are Predicted Antifungal Targets?J Fungi (Basel). 2020 Sep 30;6(4):198. doi: 10.3390/jof6040198. J Fungi (Basel). 2020. PMID: 33007839 Free PMC article. Review.
-
Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs from Natural Sources.Pharmaceuticals (Basel). 2020 Sep 15;13(9):248. doi: 10.3390/ph13090248. Pharmaceuticals (Basel). 2020. PMID: 32942693 Free PMC article. Review.
References
-
- Arikan, S., and J. H. Rex. 2001. Nystatin LF (Aronex/Abbott). Curr. Opin. Investig. Drugs 2:488-495. - PubMed
-
- Ascioglu, S., J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, and T. J. Walsh. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14. - PubMed
-
- Carrillo-Munoz, A. J., G. Quindos, C. Tur, M. T. Ruesga, Y. Miranda, O. del Valle, P. A. Cossum, and T. L. Wallace. 1999. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J. Antimicrob. Chemother. 44:397-401. - PubMed
-
- Denning, D. W. 1996. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23:608-615. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical